Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data

Tanriverdi et al., Turkish Journal of Medical Sciences, doi:doi:10.3906/sag-2005-82
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 83 hospitalized patients in Turkey confirming that earlier treatment is better, and showing that the addition of AZ to HCQ reduced hospitalization time.
Tanriverdi et al., 26 Feb 2021, peer-reviewed, 8 authors.
This PaperHCQAll
Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data
Elif Tanriverdi, Mustafa Çörtük, Binnaz Zeynep Yildirim, Efsun Gonca Uğur Chousein, Demet Turan, Halit Çinarka, Mehmet Akif Özgül, Erdoğan Çetinkaya
TURKISH JOURNAL OF MEDICAL SCIENCES, doi:10.3906/sag-2005-82
Background/aim: New treatment regimens for COVID-19, which has threatened the world recently, continue to be investigated. Although some of the treatments are promising, it is thought to be early to state that there is definitive treatment. Experiences and treatment protocol studies from treatment centers are still important. The aim of this study is to evaluate factors affecting the treatment process of the first cases followed in our clinic. Materials and methods: The consecutive hospitalized patients with COVID-19 pneumonia were analyzed in this retrospective and cross-sectional study. Data were recorded from the electronic and written files of patients. Results: Eighty-three patients were evaluated. The median age was 50 ± 15 years. Forty-eight (57.8%) patients had one or more comorbidities. The most common comorbidity was hypertension. The most common symptom was cough in 58 patients (70%). The overall mortality was 15%, and 85% of the patients were discharged. The time between the onset of symptoms and hospitalization was statistically significantly longer in deceased patients (P = 0.039). Age, D-Dimer, troponin, CK, CK-MB, ferritin, procalcitonin, and neutrophil to lymphocyte ratio were statistically significantly higher in deceased patients than survivor patients. In subgroup analysis, in the patients receiving azithromycin plus hydroxychloroquine and other antibiotics plus hydroxychloroquine, the duration of hospitalization was shorter in the azithromycin group (P = 0.027). Conclusion: Early treatment and early admission to the hospital can be crucial for the better treatment process. Combination therapy with azithromycin may be preferred in the first treatment choice because it can shorten the length of hospital stay.
Each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content. Conflicts of interest The authors do not have any conflict of interest or financial disclosure. No funding was received for the study. The article or the content is not under consideration or has not been published by any other journal. Ethical approval Ethics committee approval was received for this study from Hamidiye Scientific Research Ethics Committee of University of Health Sciences Turkey (2020/3/54). Consent form from patients was not received because of being a retrospective study.
References
Dai, Zhang, Xia, Zhang, Shang, High-resolution chest CT features and clinical characteristics of patients infected with COVID-19 in Jiangsu, China, International Journal of Infectious Disease, doi:10.1016/j.ijid.2020.04.003
Du, Liang, Yang, Wang, Cao, Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study, European Respiratory Journal, doi:10.1183/13993003.00524-2020
Gautret, Lagier, Parola, Hoang, Meddeb, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101663
Kim, Chin, Kang, Kim, Kang, Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19, Journal of Korean Medical Science, doi:10.3346/jkms.2020.35.e142
Li, Chen, Critical patients with coronavirus disease 2019: Risk factors and outcome nomogram, The Journal of Infection, doi:10.1016/j.jinf.2020.03.025
Liu, Du, Chen, Jin, Peng, Neutrophil-tolymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19, The Journal of Infection, doi:10.1016/j.jinf.2020.04.002
Megarbane, Scherrmann, Hydroxychloroquine and azithromycin to treat patients with COVID-19: both friends and foes?, Journal of Clinical Pharmacology, doi:10.1002/jcph.1646
Ministry, COVID-19 (SARS-CoV2 Infection) Guide
Molina, Delaugerre, Goff, Lima, Ponscarme, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Medecine et Maladies Infectieuses, doi:10.1016/j.medmal.2020.03.006
Vincent, Taccone, Understanding pathways to death in patients with COVID-19, The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30165-X
Yang, Yang, Wang, Wu, Xu, Thrombocytopenia and its association with mortality in patients with COVID-19, Journal of Thrombosis and Haemostasis, doi:10.1111/jth.14848
Yavuz, Ünal, Antiviral treatment of COVID-19, Turkish Journal of Medical Sciences, doi:10.3906/sag-2004-145
Yi, Lagniton, Ye, Li, Xu, COVID-19: what has been learned and to be learned about the novel coronavirus disease, Int J Biol Sci, doi:10.7150/ijbs.45134
Zheng, Tang, Li, Huang, Xie, Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha, European Review for Medical and Pharmacological Sciences, doi:10.26355/eurrev_202003_20711
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit